Lorazepam
This medication contains lorazepam, which belongs to a group of medicines called benzodiazepines. The medication helps to relieve anxiety and muscle tension.
Lorabex is usually indicated for premedication before surgery or before invasive or prolonged diagnostic examinations. It may also be used to relieve acute anxiety states, acute excitement, or acute mania, and to control seizures.
If there is no improvement or if the patient feels worse after taking Lorabex, they should inform their doctor.
Lorabex should not be used in children under 12 years of age, except for the control of seizures, in which case Lorabex may be used in adults, children, and infants from 1 month of age and older.
Tell your doctor or pharmacist if you have taken Lorabex before taking any other medication, if you are pregnant, or if you are admitted to the hospital for treatment.
Before starting treatment with Lorabex, discuss with your doctor, pharmacist, or nurse:
If the patient is being treated on an outpatient basis, Lorabex should not be administered unless the patient is accompanied by an escort who can take them home.
Tolerance to benzodiazepines may occur, so after a few weeks of using Lorabex, the effect may be less noticeable.
Lorazepam may cause dependence, especially in patients who have previously abused drugs, narcotics, and/or alcohol.
It is unlikely that dependence will occur, but the risk increases with higher doses and longer use, and is further increased in patients who have been dependent on alcohol, drugs, or narcotics in the past, or in patients with marked personality disorders. Therefore, lorazepam should be avoided in individuals dependent on alcohol, drugs, or narcotics.
Dependence can lead to withdrawal symptoms, especially in the case of sudden discontinuation of treatment. Therefore, the medication should always be discontinued gradually - if necessary, using lorazepam orally.
Some patients may feel drowsy after taking Lorabex. It is recommended to stay in the hospital for at least 8 hours or overnight after receiving the injection. If the patient is to leave the hospital soon after receiving Lorabex, they should be under the care of an escort.
In some elderly patients, dizziness may occur after taking Lorabex, and these patients are at increased risk of falls.
Transient memory loss has been reported after administration of benzodiazepines.
Lorabex should not be used in children under 12 years of age, except for the control of seizures. In the case of seizures, Lorabex should not be used in newborns.
Tell your doctor or pharmacist about all medications you are currently taking, or have recently taken, and about any medications you plan to take.
In particular, inform your doctor about taking any other sedative, anxiolytic, antidepressant, strong pain-relieving (e.g., opioids, methadone - the dose and duration of both medications should be minimized according to the doctor's recommendations), antiepileptic, antihistamine, or psychotropic medications for mood or mental disorders (e.g., haloperidol or chlorpromazine). Taking Lorabex with pain-relieving medications increases the risk of drowsiness, and in rare cases, breathing difficulties, and may result in death.
Barbiturates (sedatives) and anesthetics (medications that cause reversible loss of sensation), clozapine (a medication for mood or mental disorders), sodium valproate (used to treat epilepsy and bipolar affective disorder), probenecid (a medication used to treat gout), theophylline, aminophylline (medications used to treat respiratory diseases), disulfiram (a medication that supports the treatment of alcoholism), and metronidazole (an antibiotic): it may be necessary to reduce the doses of these medications before administering Lorabex. You should also inform your doctor about taking a medication called scopolamine, which may be used for intestinal problems or before surgery.
Tell your doctor or pharmacist if you have taken Lorabex before taking any other medication, if you are pregnant, or if you are admitted to the hospital for treatment.
Alcohol should be avoided for 24 to 48 hours before taking Lorabex. See section 3.
If you are pregnant or breastfeeding, think you may be pregnant, or are planning to have a child, ask your doctor or pharmacist for advice before taking this medication.
Pregnancy
Benzodiazepines, including Lorabex, may cause fetal harm if administered early in pregnancy. Therefore, if you are pregnant or may become pregnant, you should not take this medication without consulting your doctor. If you take this medication during late pregnancy or during childbirth, the newborn may be less active than other children, and symptoms such as low body temperature, decreased muscle tone, breathing difficulties, or feeding difficulties may occur. The newborn may also experience transient disturbances in thermoregulation. If the mother takes lorazepam regularly for a prolonged period during late pregnancy, the newborn may experience withdrawal symptoms.
Breastfeeding
Lorabex should not be administered to breastfeeding mothers unless, in the doctor's opinion, the expected benefits to the mother outweigh the risk to the baby, as the medication may pass into breast milk.
On the day of taking Lorabex, some patients may experience drowsiness or dizziness.
Do not drive or operate machinery for 24 to 48 hours after taking Lorabex.
Lorabex contains 20.9 mg of benzyl alcohol, 828.3 mg of propylene glycol, and 202.3 mg of macrogol per ml.
In children under 5 years of age, patients with liver or kidney disease, or pregnant or breastfeeding women, consult your doctor or pharmacist before using the medication, as the excipients may cause side effects. The doctor may adjust the dose if the patient or child is taking other medications containing benzyl alcohol, propylene glycol, or alcohol.
Benzyl alcohol may cause allergic reactions.
Administration of benzyl alcohol to small children is associated with a risk of severe side effects, including gasping syndrome, but Lorabex is not used in infants under 1 month of age.
Do not administer to small children (under 3 years of age) for more than a week without the advice of a doctor or pharmacist.
Always take this medication exactly as your doctor has told you. If you are not sure, ask your doctor or pharmacist.
The doctor will administer Lorabex by injection into a vein or into a muscle.
The recommended dose is:
In premedication, the usual dose is 0.05 mg per kilogram of body weight (e.g., if the patient weighs 70 kilograms, they will probably receive 3.5 mg of lorazepam).
Lorabex should not be used in premedication in children under 12 years of age.
In acute anxiety, the usual dose is 0.025 to 0.03 mg per kilogram of body weight (e.g., if the patient weighs 70 kilograms, they will probably receive 1.75 to 2.1 mg of lorazepam).
Lorabex should not be used to treat acute anxiety in children under 12 years of age.
The doctor may prescribe a different dose or recommend a different treatment duration, especially in elderly or weakened patients.
Patients with kidney or liver function disorders: smaller doses may be sufficient in these patients. Use in patients with severe liver failure is contraindicated.
In controlling seizure states in adults, lorazepam is usually administered intravenously, in a dose of 4 mg. Children receive a lower dose of 0.1 mg per kilogram of body weight intravenously. Do not exceed 4 mg per dose. If seizures persist within 10-15 minutes after administration, the doctor may decide to administer a second dose.
Due to the potential risk of toxicity associated with the accumulation of excipients, the maximum dose of Lorabex should not be repeated within 24 hours in children under 5 years of age.
Lorabex should not be used in children under 12 years of age, except for the control of seizures (see also section 2). In the case of seizures, Lorabex should not be used in newborns (see also section 2).
Lorabex is Usually Prescribed in One or Two Doses or for a Short Period of Treatment.
This reduces the risk of dependence on Lorabex or the occurrence of withdrawal symptoms after discontinuation of treatment (see "Discontinuing Lorabex" below).
The doctor will prescribe the smallest effective dose for the shortest possible duration.
If Lorabex is administered in doses significantly higher than those listed above, the risk of side effects, such as those listed in section 4 "Possible Side Effects", increases. Inform your doctor if you experience any of these symptoms or other side effects.
After completing treatment with Lorabex, the doctor will decide whether further treatment is necessary.
After completing treatment, the dose of Lorabex should be gradually reduced. This will allow the body to get used to the absence of Lorabex and reduce the risk of side effects.
After discontinuing Lorabex, withdrawal symptoms may occur, such as headache, muscle pain, anxiety, tension, depression, restlessness, dizziness, nausea, diarrhea, loss of appetite, insomnia, confusion, irritability, excitement, tremors, abdominal pain, changes in heart rate, short-term memory loss, dysphoria (feeling of sadness, anxiety, irritability, or restlessness), high fever, and sweating. If these symptoms occur, they usually do not last long. If you experience any of these symptoms, contact your doctor.
If you experience any of the following withdrawal symptoms: loss of reality, feeling of unreality or detachment from life, and inability to feel emotions, ringing in the ears, numbness or tingling of hands or feet, vomiting, tremors, hallucinations, seizures, or effects on vision, hearing, or touch, contact your doctor immediately.
If you have any further questions about using this medication, ask your doctor or pharmacist.
Like all medications, Lorabex can cause side effects, although not everybody gets them.
If you experience any of the following serious side effects (frequency: unknown (frequency cannot be estimated from the available data)), contact your doctor immediately or seek medical attention:
In rare cases, patients may experience pain, inflammation, or rash at the injection site. If this occurs, inform your doctor.
During treatment with Lorabex, side effects may occasionally occur. They are usually not severe and do not last long. However, inform your doctor if any of the following side effects are severe or troublesome.
Very Common(occurring in more than 1 in 10 patients):
Common(occurring in less than 1 in 10 patients):
Uncommon(occurring in less than 1 in 100 patients)
Frequency Not Known(frequency cannot be estimated from the available data):
The following side effects may be more likely to occur in children and elderly patients:
If you experience any side effects, including any not listed in this leaflet, please inform your doctor.
If you experience any side effects, including any not listed in this leaflet, please inform your doctor or pharmacist. Side effects can be reported directly to the Department of Drug Safety Monitoring of the Office for Registration of Medicinal Products, Medical Devices, and Biocidal Products
Al. Jerozolimskie 181C
02-222 Warsaw
Phone: +48 22 49 21 301
Fax: +48 22 49 21 309
Website: https://smz.ezdrowie.gov.pl
Side effects can also be reported to the marketing authorization holder.
Reporting side effects will help to gather more information on the safety of this medication.
Keep the medication out of the sight and reach of children.
Store and transport in a cool place (2°C-8°C). Store in the original packaging to protect from light. The chemical and physical stability of the medication has been demonstrated after dilution for 1 hour at 2°C-8°C. From a microbiological point of view, unless the method of opening/dilution excludes the risk of microbial contamination, the medication should be used immediately. If not used immediately, the user is responsible for the storage conditions prior to use.
Do not use this medication after the expiry date stated on the label and carton after: EXP.
The expiry date refers to the last day of the month stated.
The notation on the packaging after the abbreviation EXP indicates the expiry date, and after the abbreviation Lot indicates the batch number.
Medications should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medications that are no longer needed. This will help protect the environment.
Clear, colorless or almost colorless solution.
Lorabex is packaged in clear, colorless glass type I ampoules, with a capacity of 2 ml. Each ampoule contains 1 ml of solution.
The ampoules are placed on PVC trays, wrapped in transparent PE foil. The PVC trays are in a cardboard box with a package leaflet.
Lorabex is packaged in 5 or 10 ampoules of 1 ml solution each.
Not all pack sizes may be marketed.
Polpharma S.A.
ul. Pelplińska 19, 83-200 Starogard Gdański
phone: +48 22 364 61 01
Medochemie Ltd
48 Iapetou Street, Agios Athanassios Industrial Area
4101 Limassol
Cyprus
Dosage and duration of treatment should be determined for each patient individually.
Use the lowest effective dose for the shortest possible duration. The risk of withdrawal syndrome and rebound phenomenon is greater after sudden discontinuation of treatment; therefore, the medication should be discontinued gradually in all patients.
Adults: 0.05 mg/kg body weight (3.5 mg at an average body weight of 70 kg). The medication should be administered intravenously 30-45 minutes before surgery, sedative effects occur within 5-10 minutes, and loss of consciousness occurs within 30-45 minutes.
The medication should be administered intramuscularly 1-1.5 hours before surgery, sedative effects occur within 30-45 minutes, and loss of consciousness occurs within 60-90 minutes.
Children and Adolescents: Lorabex should not be used in children under 12 years of age.
Adults: 0.025-0.03 mg/kg body weight (1.75-2.1 mg at an average body weight of 70 kg). Repeat every 6 hours.
Children and Adolescents: Lorabex should not be used in children under 12 years of age.
Adults: 4 mg intravenously.
Children and Adolescents(from 1 month of age and older): 0.1 mg/kg body weight intravenously.
Maximum 4 mg per dose.
Due to the potential risk of toxicity associated with the accumulation of excipients, the maximum dose of Lorabex should not be repeated within 24 hours in children under 5 years of age.
In the case of seizure states, Lorabex should not be used in newborns.
If seizures persist within 10-15 minutes after administration, the dose may be repeated, but do not exceed 4 mg per dose.
Elderly and Weak Patients: Elderly and weak patients may respond to lower doses, and half of the recommended dose for adults may be sufficient.
Lower doses may be sufficient in patients with kidney or liver function disorders. Administration in patients with severe liver failure is contraindicated.
In elderly and weak patients, the initial dose should be reduced by about 50% and the dose adjusted according to the patient's needs and tolerance.
Lorabex can be administered intravenously or intramuscularly, but the intravenous route is preferred.
Caution should be exercised when administering the medication to avoid intra-arterial or small vein injection.
Absorption from the injection site is significantly slower in the case of intramuscular administration, and similar efficacy can be achieved with oral administration of lorazepam tablets.
Lorabex should not be used for prolonged periods.
Intramuscular administration:
To facilitate intramuscular administration, it is recommended to dilute Lorabex in a 1:1 ratio with 0.9% sodium chloride solution, 5% glucose solution, or water for injection.
Intravenous administration:
In the case of intravenous administration, Lorabex should always be diluted with 0.9% sodium chloride solution, 5% glucose solution, or water for injection in a 1:1 ratio.
Lorabex is available as a 1 ml solution in a 2 ml ampoule to facilitate dilution.
Lorabex should not be mixed with other medications in the same syringe.
Due to the lack of data on compatibility, this medication should not be mixed with other medications, except for those listed in the "Dosage and Administration" section.
Before opening: 18 months.
Stability after dilution:
The following table shows the chemical and physical stability of the medication during storage at 2°C-8°C (in the refrigerator) and at 25°C, depending on the diluent used and the concentration of lorazepam:
Lorazepam Concentration | Diluent | Stability [hours] | |
2°C-8°C | 25°C | ||
0.5 mg/ml | water for injection | 2 | 1 |
0.9% sodium chloride solution | 8 | use immediately | |
5% glucose solution | 4 | use immediately | |
1.0 mg/ml | water for injection | 4 | 3 |
0.9% sodium chloride solution | 8 | 3 | |
5% glucose solution | 4 | 3 |
From a microbiological point of view, unless the method of opening/dilution excludes the risk of microbial contamination, the medication should be used immediately. If not used immediately, the user is responsible for the storage conditions prior to use.
Store and transport in a cool place (2°C-8°C).
Store in the original packaging to protect from light.
Lorabex should not be mixed with other medications in the same syringe. Do not use if the solution has discolored or precipitated (see "Dosage and Administration").
No special requirements for disposal.
Any unused medicinal product or waste material should be disposed of in accordance with local requirements.
Need help understanding this medicine or your symptoms? Online doctors can answer your questions and offer guidance.